Home > Newsletters > Drug Industry Daily > FDA Extends Review of Two Novo Nordisk Diabetes Candidates by Three Months
Drug Industry Daily
June 11, 2012 | Vol. 11 No. 114
FDA Extends Review of Two Novo Nordisk Diabetes Candidates by Three Months
Novo Nordisk will have to wait until late October to get word on the fate of two ultra-long-acting insulin treatments because the FDA needs additional time to review data clarifications and analyses it requested after the initial NDA submissions.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.